Core Viewpoint - Shenzhen Hanno Medical Technology Co., Ltd. is the first domestic company to successfully develop and obtain approval for the ECMO (Extracorporeal Membrane Oxygenation) system, aiming for an IPO on the Sci-Tech Innovation Board by the end of 2025, despite currently not being profitable and facing significant financial challenges [1][3][9]. Financial Performance - Hanno Medical has reported continuous losses over the past three and a half years, with cumulative losses exceeding 600 million yuan, and net profits for 2022, 2023, and the first half of 2025 being -64.79 million yuan, -341 million yuan, and -82.27 million yuan respectively [3][7]. - The company's revenue from its core product, Lifemotion ECMO system, has been limited, with reported revenues of approximately 0 yuan, 29.83 million yuan, 49.31 million yuan, and 37.35 million yuan for the respective years [7]. - The cash flow from operating activities has consistently been negative, with figures of -84.01 million yuan, -35.19 million yuan, -119 million yuan, and -71.57 million yuan during the same periods [9]. Market Potential - The ECMO market in China is projected to grow significantly, reaching 3.71 billion yuan by 2030, with a compound annual growth rate (CAGR) of 25.2% from 2024 to 2030, and 10.73 billion yuan by 2035, with a CAGR of 23.7% from 2030 to 2035 [6]. - The demand for ECMO treatment is increasing, with a notable gap in device availability per capita compared to developed countries, indicating substantial market potential for domestic products [6]. Challenges and Barriers - Hanno Medical faces several barriers to commercializing its ECMO system, including high technical and cost barriers, market monopolization by imported brands, inadequate clinical training and support systems, and a lengthy profitability cycle due to high initial R&D and market entry costs [8]. - The company's asset-liability ratio has been rising, reaching 72.36% by the latest reporting period, significantly higher than the industry average, which raises concerns about financial stability and the ability to cover interest expenses [9][10]. IPO and Future Plans - Following the acceptance of its IPO application on December 23, 2025, Hanno Medical was selected for a site inspection as part of the regulatory process, which aims to enhance the quality of listed companies and prevent financial fraud [4][5]. - The company plans to raise 1.062 billion yuan through its IPO, which will be allocated to R&D center construction, production base development, marketing network establishment, and working capital supplementation [11].

Core Viewpoint - Shenzhen Hanno Medical Technology Co., Ltd. is the first domestic company to successfully develop and obtain approval for the ECMO system, aiming for an IPO on the Sci-Tech Innovation Board by the end of 2025, despite currently not being profitable and facing significant financial challenges [1][4]. Financial Performance - The total assets of Hanno Medical as of June 30, 2025, are approximately 496.07 million yuan, with a continuous increase in asset-liability ratio, reaching 72.36% [2][10]. - The company reported net profits of -64.79 million yuan in 2022, -341 million yuan in 2023, -182.79 million yuan in 2024, and -82.27 million yuan in the first half of 2025, accumulating losses exceeding 600 million yuan over three and a half years [4][8]. - Operating revenues for the same periods were approximately 0 yuan in 2022, 29.83 million yuan in 2023, 49.31 million yuan in 2024, and 37.35 million yuan in the first half of 2025 [8]. Market Potential - The ECMO market in China is expected to grow significantly, projected to reach 3.71 billion yuan by 2030, with a compound annual growth rate (CAGR) of 25.2% from 2024 to 2030, and 10.73 billion yuan by 2035, with a CAGR of 23.7% from 2030 to 2035 [6]. Challenges in Commercialization - Hanno Medical faces several barriers to the commercialization of its ECMO system, including high technical and cost barriers, market monopolization by imported brands, inadequate clinical training and support systems, and a lengthy profitability cycle due to substantial upfront R&D and market investment [8][9]. IPO and Regulatory Scrutiny - Hanno Medical's IPO application was accepted on December 23, 2025, and the company was selected for on-site inspection as part of the first batch of enterprises for 2026, highlighting the importance of regulatory oversight in ensuring the quality of listed companies [5][11].